Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT02634463
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
- Conditions
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study siteDrug: Paliperidone palmitateDrug: ChlorpromazineDrug: DroperidolDrug: FluphenazineDrug: HaloperidolDrug: LoxapineDrug: PerphenazineDrug: PimozideDrug: ProchlorperazineDrug: ThiothixeneDrug: ThioridazineDrug: TrifluoperazineDrug: AripiprazoleDrug: AsenapineDrug: ClozapineDrug: IloperidoneDrug: OlanzapineDrug: PaliperidoneDrug: QuetiapineDrug: RisperidoneDrug: Ziprasidone
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
Combination Treatment for Augmenting Language in Children With ASD
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 58
- Registration Number
- NCT02574741
- Locations
- 🇺🇸
University of California, Los Angeles, California, United States
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 136
- Registration Number
- NCT02534363
- Locations
- 🇪🇸
University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
- First Posted Date
- 2015-08-25
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 200
- Registration Number
- NCT02532491
- Locations
- 🇪🇸
University Hospital Marques de Valdecilla, Santander, Cantabria, Spain
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up
- Conditions
- Interventions
- First Posted Date
- 2015-08-18
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Fundación Marques de Valdecilla
- Target Recruit Count
- 203
- Registration Number
- NCT02526030
- Locations
- 🇪🇸
University Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- CMG Pharmaceutical Co. Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT02501109
A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry
- Conditions
- Interventions
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 9
- Registration Number
- NCT02462473
A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2015-09-21
- Target Recruit Count
- 631
- Registration Number
- NCT02435836
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 337
- Registration Number
- NCT02431702
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.